Amita Gupta, MD, MHS

CRS:

BJMCJHU

Role:

Investigators

Position:

Principal Investigator, Johns Hopkins Professor of Medicine and Public Health; Deputy Director, CCGHE

Email:

agupta25@jhmi.edu

Dr. Gupta is Deputy Director of the Johns Hopkins (JH) Center for Clinical Global Health Education (CCGHE), and Professor of Infectious Diseases at the JH School of Medicine, with a joint appointment in International Health at the JH Bloomberg School of Public Health.

Board certified by the American Board of Internal Medicine in infectious diseases, Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, tuberculosis (TB), and antimicrobial resistant infections. Since 2003, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations. She serves in leadership positions as the US chair for the Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. She also serves on the global RePORT International Executive Committee, a multilateral global consortia for TB research. She is Co-principal Investigator of the NIH-funded Baltimore-Washington-India HIV and Infectious Diseases Clinical Trials Unit (BWI-CTU), and she is an active clinical investigator in multi-country trials conducted by the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT), and has served as protocol chair for high impact studies that have resulted in publications in The New England Journal of Medicine and The Lancet. She is Co-chair of the NIH and AmFAR funded IeDea HIV/TB Working Group and Scientific Committee co-Chair for IMPAACT TB. 

She has been awarded research grants from the NIH, CDC, UNITAID, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond. Learn about CCGHE India Research Partnerships In 2019, Dr. Gupta was appointed by the US Health and Human Services Secretary for a 4-year term to the NIAID Council, the chief advisory committee for National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health. In 2020, she was invited to the Governing Board of the Indo-U.S. Science & Technology Forum. 

Dr. Gupta is an author of more than 180 peer-reviewed research publications and 7 book chapters on prevention and treatment of HIV, TB, and other infectious diseases, primarily in low- and middle-income settings. She has also mentored more than 35 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications.

Dr. Gupta received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from JH Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention (CDC, Foodborne and Diarrheal Diseases) and at the JHU School of Medicine (Infectious Diseases).

Publications on PubMed

Research Program Building and Leadership

  • 2007-present: Chair, IMPAACT P1078, A Randomized Clinical Trial to Evaluate the Safety of Immediate (antepartum-initiated) Versus Deferred Reduction in TB Incidence and Mortality Among HIV-Infected Women and Their Infants in High TB Incidence Settings
  • 2008-present: Protocol Vice-Chair of ACTG 5274, Reducing Early Mortality Among Patients with Advanced HIV Disease: A Randomized Strategy Trial Comparing the Safety and Efficacy of an Individualized Patient TB Treatment Approach to a Public Health Pre-emptive TB Treatment Approach in Resource-Limited Settings (REMEMBER)
  • 2008-2012: Co-investigator ACTG 5267, A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Health Volunteers
  •  2008-2012: Co-investigator ACTG 5253 Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
  • 2009-present: Protocol Vice Chair ACTG 5279, Phase III Clinical Trial of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Adults with Latent Tuberculosis Infection
  • 2010: Invited by NIAID, NIH to be a part of a NIH delegation to assess scope of TB research in India. Accompanied the Deputy Director of the Division of AIDS, the Associate Director of International Health Programs, NIAID and other NIH delegates on site visits to 15 Indian institutions throughout the country
  • 2011-2012: Selected to participate in the Johns Hopkins School of Medicine’s Office in Science and Medicine (OWISM) Leadership Program for Women Faculty
  • 2012-present: Member, ACTG TB Transformative Science Group
  • 2014-present: IMPAACT TB Scientific Committee Vice-Chair
  • 2014-present: Co-investigator IMPAACT 2001 Protocol Team, PK and Safety of INH and Rifapentine in Pregnancy
  • 2014-2016: US Co-chair, NIH-India Government, Regional Prospective Observational Research in Tuberculosis (RePORT)
  • 2014-present: Co-chair PHOENIX ACTG A5300/IMPAACT 2003 feasibility study and MDR TB contact prophylaxis trial

Large Multi-country Trial Ongoing

  • 2015-present: Member, Union Interest Group in Maternal-Infant TB working group
  • 2018-present: co Chair, IeDEA TB working group
  • 2016-present: US Chair, TB Research Consortium, RePORT India
  • 2016-present: Member, Executive Committee, RePORT International
  • 2017: Selected to participate in the Johns Hopkins Leadership Development Program (LDP)
  • 2018: Participant, Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, WHO Report generation
  • 2019-present: NIAID Council
  • 2020-present: Governing Board Member, Indo-US Science and Technology Forum (IUSTTF)
  • Nimkar S, Kinikar A, Chavan A, Sangle S, Rewari B, Gupta G, Mave V, Marbaniang I. High prevalence of late presentation of ART-naïve perinatally infected children for care in Pune, India. AIDS Care. 2020 Feb 19:1-6. PMID: 32070118.
  • Miyahara S, Ramchandani R, Montepiedra G, Kim S, Gupta A, Swindells S, Chaisson R. Applying risk benefit analysis to outcomes from TB clinical trials. Clin Infect Dis. 2020 Feb 3;70(4):698-703. doi: 10.1093/cid/ciz784. PMID: 31414121.
  • Deshmukh S, Atre S, Ramchandra, Chavan A, Raskar S, Mave V, Gupte N, Gaikwad S, Sahasrabudhe Tushar, Barthwal M, Kakrani A, Kagal A, Gupta A, Bharadwaj R, Pradhan N, Dharmshale S, Golub J. Assessment of the Xpert assay among new pulmonary tuberculosis suspects with and without diabetes mellitus. Int J Tuberc Lung Dis. 1 Jan 2020: 24(1); 11-117(5). doi: https://doi.org/10.5588/ijtld.19.0239
  • Yukari C Manabe, MD; Bruno B Andrade; Nikhil Gupte; Samantha Leong; Manisha Kintali; Mitch Matoga; Cynthia Riviere; Wadzanai Sameneka; Javier R Lama; Kogieleum Naidoo; Yue Zhao; William Evan Johnson; Jerrold Ellner, MD; Mina C Hosseinipour; Gregory P Bisson; Padmini Salgame, PhD; Amita Gupta, MD. A parsimonious host inflammatory biomarker signature predicts incident TB and mortality in advanced HIV. Clin Infect Dis. 2019 Nov 25. pii: ciz1147. doi: 10.1093/cid/ciz1147. [Epub ahead of print]. PMID: 31761933.
  • Shivakoti R, Dalli J, Kadam D, Gaikwad S, Barthwal M, Colas RA, Mazzacuva F, Lokhande R, Dharmshale S, Bharadwaj R, Kagal A, Pradhan N, Deshmukh S, Atre S, Sahasrabudhe T, Kakrani A, Kulkarni V, Raskar S, Suryavanshi N, Chon S, Gupte A, Gupta A, Gupte N, Arriaga MB, Fukutani KF, Andrade BB, Golub JE, Mave V. Lipid mediators of inflammation and resolution in individuals with tuberculosis and tuberculosis-diabetes. Prostaglandins Other Lipid Mediat. 2019 Nov 11;147:106398. doi: 10.1016/j.prostaglandins.2019.106398. [Epub ahead of print]. PMID: 31726221.
  • Gupte AN, Kadam D, Sangle S, Rewari BB, Salvi S, Chavan A, Nimkar S, Golub J, Gupte N, Gupta A, Marbaniang I, Mave V. Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India. BMC Infect Dis. 2019 Oct 29;19(1):914. doi: 10.1186/s12879-019-4569-z. PMID: 31664933; PMCID: PMC6820927.
  • Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC (2019) Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med 16(8): e1002882. https://doi.org/10.1371/journal.pmed.1002882. PMID: 31415563; PMCID: PMC6695091.
  • Marbaniang I, Sangle S, Salvi S, Kulkarni K, Shere D, Deshpande P, Nimkar S, Gupta A, Mave V. High prevalence of insulin resistance and occurrence prior to hyperinsulinemia threshold among people living HIV in Pune, India. Diabetes Metabolic Syndrome: Clinical Research & Reviews. May-June 2019;13(3):1813-1819.
  • Suryavanshi N, Murrill M, Gupta A, Hughes M, Hesseling A, Kim S, Naini L, Jones L, Smith B, Gupte N, Dawson R, Mave V, Meshram S, Mendoza A, Sanches J, Kumarasamy N, Comins K, Conradie F, Shenje J, Fountain SN, Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi U, Garcia Ferreira AC, Okeyo E, Swindells S, Churchyard G, Shah NS for the A5300/I2003 Study Team. Willingness to take multidrug-resistanat tuberculosis (MDR-TB) preventive therapy among adult and adolescent household contacts of MDR-TB index cases: An international multi-site cross-sectional study. Clin Infect Dis. 2019 Mar 28. pii: ciz254. doi: 10.1093/cid/ciz254. [Epub ahead of print] PMID: 30919881.
  • Hoffman RM, Angelidou KN, Brummel SS, Saidi F, Violari A, Dula D, Mave V, Fairlie L, Theron G, Kamateeka M, Chipato T, Chi BH, Stranix-Chibanda L, Nematadzira T, Moodley D, Bhattacharya D, Gupta A, Coletti A, McIntyre JA, Klingman KL, Chakhtoura N, Shapiro DE, Fowler MG, Currier JS for the IMPAACT PROMISE 1077BF/FF team. Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. HIV Clin Trials. 2018 Dec;19(6):209-224. doi: 10.1080/15284336.2018.1537327. PMID: 30890061; PMCID: PMC6428202.
  • Patil S, Kadam D, Mehtani N, Sangle S, Marbaniang I, Kulkarni V, Shere D, Dhumal G, Suryavanshi N, Gupte N, Bollinger R, DeLuca A, Nevarekar N, Menon P, Kawade R, Patil M; Gupta A, Mave V. Elevated Highly Sensitive C-Reactive Protein and D-dimer Levels are Associated with Food Insecurity among People Living with HIV in Pune, India. Public Health Nutr. 2019 Mar 4:1-8. doi: 10.1017/S136898001900020X. [Epub ahead of print] PMID: 30827288.
  • Alexander M, Gupta A, Mathad JS. Is there a connection between gestational diabetes, HIV, and tuberculosis? Int J Tuberc Lung Dis. 2019 Jan1;23(1):19-25(7). doi: https://doi.org/10.5588/ijtld.18.0337. PMID: 30674375.
  • Swindells S, Gupta A, Kim S, Hughes MD, Sanchez J, Mave V, Dawson R, Kumarasamy N, Comins K, Smith B, Rustomjee R, Naini L, Shah NS, Hesseling A, Churchyard G for the ACTGA5300/IMPAACT 2003 PHOENIx Feasibility Study Team. Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). Int J Tuberc Lung Dis 22(9):1016-1022, 2018 The Union, http://dx.doi.org/10.5588/ijtld.18.0163.
  • Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Ganashanmugam D, Chakhtoura N, McCarthy K, ,Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT, Masenya M, Nyati M, Theron G, Mulenga H, Butler K, Shapiro DE, PROMISE Study Team. Prevention of HIV-1 transmission through breastfeeding: efficacy of safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open-label, clinical trial. J Acquir Immune Defic Syndr 2018 Apr 1:77(4):383-392. doi: 10.1097/QAI.0000000000001612. PMID: 29239901, PMCID: PMC5825265.
  • Kapoor S, Gupta A, Shah M. Cost effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India. Int J Tuberc Lung Dis. 2016:20(1).
  • Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, Dooley KE, Gupta A, Gandhi M. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. International Journal of Tuberculosis and Lung Disease. 2016 Jun;20(6):844-7. doi: 10.5588/ijtld.15.0882 
  • Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, Kirui FK, Badal-Faesen S, MBBCh, Lagat D, Nyirenda M, Naidoo K, Hakim J, Mugyenyi P, Henostroza G, Leger PD, Lama JR, Mohapi L, Alave J, Mave V, Veloso VG, Pillay S, Kumarasamy N, Bao J, Hogg E, Jones L, Zolopa A, Kumwenda J, Gupta A, for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. The Lancet. 2016;387(10024). 
  • Mave V, Erlandson KM, Gupte N, Balgopal A, Asmuth DM, Campbell TB, Smeaton L, Kumarasamy N, Hakim J, Santos B, Riviere C, Hosseinipour MC, Sugandhavesa P, Infante R, Pillay S, Cardoso SW, Tripathy S, Mwelase N, Berendes S, Andrade BB, Thomas DL, Bollinger RC, Gupta A, and the ACTG PEARLS and NWCS 319 Study Team. Inflammation and change in body weight with antiretroviral therapy initiation in a multinational cohort of HIV-infected adults. J Infect Dis. 2016 Apr 1;213(7). doi: 10.1093/infdis/jiw096 First published online: March 8, 2016.
  • Gupta A, Montepiedra G, Gupte A, Jubulis J, Zeldow B, Detrick B, Violari A, Madhi SA, Bobat R, Cotton MF, Mitchell C, Spector SA, for the IMPAACT NWCS113 and P1041 Study Team. Low Vitamin-D levels combined with PKP3-SIGIRR-TMEM16J host variants is strongly associated with tuberculosis and death in HIV-infected and -exposed infants. PLOS ONE. 2016 Feb 12;11(2):e0148649. doi: 10.1371/journal.pone.0148649. eCollection 2016
  • Mathad J, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N, Gupte N, Joshi S, Chandanwale A, Dupnik K, Kulkarni V, Deshpande P, Fitzgerald D, Gupta A. Quantitative IFN-γ,IL-2 response and latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med. 2016 Jan 14. [Epub ahead of print].
  • Kapoor S, Gupta A, Shah M. Cost effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India. Int J Tuberc Lung Dis. 2016:20(1).
  • Maddali MV, Dowdy DW, Gupta A, Shah M. Economic and epidemiological impact of early antiretroviral therapy initiation in India. Journal of the International AIDS Society. 2015;18:20217.
  • Balagopal A, Asmuth DM, Yang W-T, Campbell T, Gupte N, Smeaton L, Kanyama C, Grinsztejn B, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li X-D, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A. Pre-cART elevation of CRP and CD4+ T-cell immune activation associated with HIV clinical progression in m Multinational case-cohort study. J Acquir Immune Def Syndr. 2015 Oct 1.
  • Suryavanshi N, Mave V, Gupte N, Bhosale R, Sambarey P, Patil S, Sastry J, Bollinger R, Gupta A, Shankar A & The SWEN India Study Team. Contraceptive use and factors associated with postpartum surgical sterilization among HIV-infected women in Pune, India. Journal of HIV/AIDS & Social Services. 2015;14(3):21 Aug [Epub ahead of print] DOI:10.1080/15381501.2014.946548
  • Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson Cam, Kim P, Fletcher CV on behalf of the ACTG A5279 Study Team. Efavirenz pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;16 Jun. pii: civ464. [Epub ahead of print]

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More